Long-term safety follow-up for WU-CART-007 treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how safe WU-CART-007 is over time after you received it. It mainly helps doctors understand long-term side effects and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received WU-CART-007 in a previous research study (an investigational study).
- You are willing to take part in follow-up visits or checks for the long-term safety study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy that uses donated immune cells to find and destroy cancer cells in patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. The goal is to see if this therapy can help achieve remission for these patients.
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.